Literature DB >> 22052359

Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.

Jane Carr-Wilkinson1, Rebecca Griffiths, Rebecca Elston, Laura D Gamble, Bojidar Goranov, Christopher P F Redfern, John Lunec, Deborah A Tweddle.   

Abstract

BACKGROUND: MYCN oncogene amplification occurs in 20-25% of neuroblastoma and is associated with a poor prognosis. We previously reported that MYCN amplified (MNA) p53 wild-type neuroblastoma cell lines failed to G1 arrest in response to irradiation, but this could not be attributed to MYCN alone. HYPOTHESIS: Genes co-amplified with MYCN and/or the predominant cell type, neuronal (N) or substrate adherent (S) phenotypes determine the downstream response to DNA damage in neuroblastoma cell lines.
METHODS: The MYCN amplicons of five MNA and two non-MNA cell line were mapped using 50K Single Nucleotide Polymorphism (SNP) arrays. One MNA (NBL-W) and one non-MNA neuroblastoma cell line (SKNSH) were sub-cloned into N and S-type cells and the p53 pathway investigated after irradiation induced DNA damage. To determine the role of p53 it was knocked down using siRNA.
RESULTS: No genes with a potential role in cell cycle regulation were consistently co-amplified in the MNA cell lines studied. High MYCN expressing NBLW-N cells failed to G1 arrest following irradiation and showed impaired induction of p21 and MDM2, whereas low MYCN expressing NBLW-S cells underwent a G1 arrest with induction of p21 and MDM2. Conversely N type cells underwent higher levels of apoptosis than S type cells. Following p53 knockdown in SHSY5Y N-type cells there was a decrease in apoptosis.
CONCLUSIONS: The downstream response to DNA damage in p53 wild-type neuroblastoma cell lines is p53 dependent, and determined both by the morphological sub-type and MYCN expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22052359     DOI: 10.4161/cc.10.21.17973

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  10 in total

Review 1.  Family matters: How MYC family oncogenes impact small cell lung cancer.

Authors:  Johannes Brägelmann; Stefanie Böhm; Matthew R Guthrie; Gurkan Mollaoglu; Trudy G Oliver; Martin L Sos
Journal:  Cell Cycle       Date:  2017-07-24       Impact factor: 4.534

2.  Putting the brakes on p53-driven apoptosis.

Authors:  Katja Höpker; Henning Hagmann; Safiya Khurshid; Shuhua Chen; Bernhard Schermer; Thomas Benzing; Hans Christian Reinhardt
Journal:  Cell Cycle       Date:  2012-09-14       Impact factor: 4.534

3.  CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.

Authors:  Sina Gogolin; Volker Ehemann; Gabriele Becker; Lena M Brueckner; Daniel Dreidax; Steffen Bannert; Ingo Nolte; Larissa Savelyeva; Emma Bell; Frank Westermann
Journal:  Cell Cycle       Date:  2013-03-05       Impact factor: 4.534

4.  Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.

Authors:  Lindi Chen; Raphaël F Rousseau; Steven A Middleton; Gwen L Nichols; David R Newell; John Lunec; Deborah A Tweddle
Journal:  Oncotarget       Date:  2015-04-30

5.  Stem Cell Markers in Neuroblastoma-An Emerging Role for LGR5.

Authors:  Helen Forgham; Darren Johnson; Noel Carter; Stephany Veuger; Jane Carr-Wilkinson
Journal:  Front Cell Dev Biol       Date:  2015-12-02

6.  Heterogeneities in Cell Cycle Checkpoint Activation Following Doxorubicin Treatment Reveal Targetable Vulnerabilities in TP53 Mutated Ultra High-Risk Neuroblastoma Cell Lines.

Authors:  Linnéa Ödborn Jönsson; Maryam Sahi; Ximena Lopez-Lorenzo; Faye Leilah Keller; Ourania N Kostopoulou; Nikolas Herold; Lars Ährlund-Richter; Shahrzad Shirazi Fard
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

Review 7.  Recent discoveries in the cycling, growing and aging of the p53 field.

Authors:  James A McCubrey; Zoya N Demidenko
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

8.  p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Authors:  Lindi Chen; Deborah A Tweddle
Journal:  Front Oncol       Date:  2012-11-28       Impact factor: 6.244

9.  Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.

Authors:  Marco Lodrini; Annika Sprüssel; Kathy Astrahantseff; Daniela Tiburtius; Robert Konschak; Holger N Lode; Matthias Fischer; Ulrich Keilholz; Angelika Eggert; Hedwig E Deubzer
Journal:  Oncotarget       Date:  2017-07-07

10.  MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

Authors:  Saurabh Agarwal; Giorgio Milazzo; Kimal Rajapakshe; Ronald Bernardi; Zaowen Chen; Eveline Barbieri; Jan Koster; Giovanni Perini; Cristian Coarfa; Jason M Shohet
Journal:  Oncotarget       Date:  2018-04-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.